Edwards Lifesciences Gets FDA Approval for TAVR in Asymptomatic Aortic Stenosis

MT Newswires Live
05-01

Edwards Lifesciences (EW) said Thursday that the US Food and Drug Administration approved its Sapien 3 transcatheter aortic valve replacement therapy, or TAVR, for asymptomatic patients with severe aortic stenosis.

The FDA approved the Sapien 3 platform, including Sapien 3, Sapien 3 Ultra, and Sapien 3 Ultra Resilia models, based on compelling results from the Early TAVR trial. The trial demonstrated better outcomes for asymptomatic severe aortic stenosis patients treated with Edwards' TAVR compared to those monitored under standard guidelines, the company said.

Price: 75.37, Change: -0.12, Percent Change: -0.16

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10